 This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, study in which patients with active RA and high A3AR expression at baseline will be randomized to the addition of either CF101 1.0 mg or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs DMARDs, including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs NSAIDS and corticosteroids must be stable for 1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments by visual analog scale, VAS, patient reported pain by VAS, a Health Assessment Questionnaire HAQ Disability Index DI, Westergren erythrocyte sedimentation rate ESR, Screening, Weeks 0 and12, and C-reactive protein CRP levels. Assessments will take place at Screening, Baseline Week 0, and at Weeks 2, 4, 8, and 12. 